Skip to Main Content

WASHINGTON — The Supreme Court will hear arguments about access to the abortion medication mifepristone on March 26.

The lawsuit is the first major test of abortion limits to go before the highest court since the same panel overturned federal abortion rights in June 2022. It also could have massive ramifications for the Food and Drug Administration’s authority.

advertisement

The FDA approved mifepristone in 2000 to be used within the first seven weeks of pregnancy. Sixteen years later, it extended that approval to 10 weeks of pregnancy. The Biden administration in 2021 removed requirements that the pill had to be taken in-person with a provider, opening the door to mail-order prescriptions.

STAT+ Exclusive Story

STAT+

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Already have an account? Log in

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect

To submit a correction request, please visit our Contact Us page.